PROTAC Library - PROTAC® / BOC Sciences

Structure	Catalog	Product Name	CAS	E3 Ligase	Target	Inquiry
	BPL-202613	3-((1H-Pyrazolo[3,4-b]pyridin-5-yl)ethynyl)-N-(4-((4-((11S,14S,15R)-15-amino-14-hydroxy-11-isobutyl-10,13-dioxo-16-phenyl-3,6-dioxa-9,12-diazahexadecyl)piperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-4-methylbenzamide	2703834-20-0	cIAP1	BCR-ABL T315I	Inquiry
Molecular Weight: 940.08 Molecular Formula: C50H60F3N9O6 Boiling Point: 1037.6±65.0°C at 760 Torr Density: 1.33±0.1 g/cm3 Description: It is a selective BCR-ABL T315I proteolysis-targeting chimeric (PROTAC) degrader based on GZD824.
	BPL-202614	3-((1H-Pyrazolo[3,4-b]pyridin-5-yl)ethynyl)-N-(4-((4-(2-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3-oxopropoxy)ethyl)piperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-4-methylbenzamide	2703834-30-2	CRBN	BCR-ABL T315I	Inquiry
Molecular Weight: 889.89 Molecular Formula: C46H42F3N9O7 Boiling Point: 1012.0±65.0°C at 760 Torr Density: 1.51±0.1 g/cm3 Description: It is a selective BCR-ABL T315I proteolysis-targeting chimeric (PROTAC) degrader based on GZD824.
	BPL-202615	3-((1H-Pyrazolo[3,4-b]pyridin-5-yl)ethynyl)-N-(4-((4-(2-(2-(2-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3-oxopropoxy)ethoxy)ethoxy)ethyl)piperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-4-methylbenzamide	2703834-32-4	CRBN	BCR-ABL T315I	Inquiry
Molecular Weight: 977.98 Molecular Formula: C50H50F3N9O9 Boiling Point: 1052.9±65.0°C at 760 Torr Density: 1.47±0.1 g/cm3 Description: It is a selective BCR-ABL T315I proteolysis-targeting chimeric (PROTAC) degrader based on GZD824.
	BPL-202616	1-(4-(4-(3-((1H-Pyrazolo[3,4-b]pyridin-5-yl)ethynyl)-4-methylbenzamido)-2-(trifluoromethyl)benzyl)piperazin-1-yl)-N-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)-3,6,9,12-tetraoxapentadecan-15-amide	2703834-33-5	CRBN	BCR-ABL T315I	Inquiry
Molecular Weight: 1022.05 Molecular Formula: C52H54F3N9O10 Boiling Point: 1073.2±65.0°C at 760 Torr Density: 1.45±0.1 g/cm3 Description: It is a selective BCR-ABL T315I proteolysis-targeting chimeric (PROTAC) degrader based on GZD824.
	BPL-202617	1-(4-(4-(3-((1H-Pyrazolo[3,4-b]pyridin-5-yl)ethynyl)-4-methylbenzamido)-2-(trifluoromethyl)benzyl)piperazin-1-yl)-N-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)-3,6,9,12,15-pentaoxaoctadecan-18-amide	2703834-34-6	CRBN	BCR-ABL T315I	Inquiry
Molecular Weight: 1066.09 Molecular Formula: C54H58F3N9O11 Boiling Point: 1093.4±65.0°C at 760 Torr Density: 1.44±0.1 g/cm3 Description: It is a selective BCR-ABL T315I proteolysis-targeting chimeric (PROTAC) degrader based on GZD824.
	BPL-202618	1-(4-(4-(3-((1H-Pyrazolo[3,4-b]pyridin-5-yl)ethynyl)-4-methylbenzamido)-2-(trifluoromethyl)benzyl)piperazin-1-yl)-N-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)-3,6,9,12,15,18-hexaoxahenicosan-21-amide	2703834-35-7	CRBN	BCR-ABL T315I	Inquiry
Molecular Weight: 1110.16 Molecular Formula: C56H62F3N9O12 Boiling Point: 1113.4±65.0°C at 760 Torr Density: 1.43±0.1 g/cm3 Description: It is a selective BCR-ABL T315I proteolysis-targeting chimeric (PROTAC) degrader based on GZD824.
	BPL-202619	3-((1H-Pyrazolo[3,4-b]pyridin-5-yl)ethynyl)-N-(4-((4-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3-oxopropyl)piperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-4-methylbenzamide	2703834-21-1	CRBN	BCR-ABL T315I	Inquiry
Molecular Weight: 845.84 Molecular Formula: C44H38F3N9O6 Boiling Point: 998.8±65.0°C at 760 Torr Density: 1.53±0.1 g/cm3 Description: It is a selective BCR-ABL T315I proteolysis-targeting chimeric (PROTAC) degrader based on GZD824.
	BPL-202620	3-((1H-Pyrazolo[3,4-b]pyridin-5-yl)ethynyl)-N-(4-((4-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-5-oxopentyl)piperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-4-methylbenzamide	2703834-22-2	CRBN	BCR-ABL T315I	Inquiry
Molecular Weight: 873.89 Molecular Formula: C46H42F3N9O6 Boiling Point: 1007.9±65.0°C at 760 Torr Density: 1.50±0.1 g/cm3 Description: It is a selective BCR-ABL T315I proteolysis-targeting chimeric (PROTAC) degrader based on GZD824.
	BPL-202621	3-((1H-Pyrazolo[3,4-b]pyridin-5-yl)ethynyl)-N-(4-((4-(6-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-6-oxohexyl)piperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-4-methylbenzamide	2703834-24-4	CRBN	BCR-ABL T315I	Inquiry
Molecular Weight: 887.92 Molecular Formula: C47H44F3N9O6 Boiling Point: 1012.2±65.0°C at 760 Torr Density: 1.48±0.1 g/cm3 Description: It is a selective BCR-ABL T315I proteolysis-targeting chimeric (PROTAC) degrader based on GZD824.
	BPL-202622	3-((1H-Pyrazolo[3,4-b]pyridin-5-yl)ethynyl)-N-(4-((4-(7-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-7-oxoheptyl)piperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-4-methylbenzamide	2703834-25-5	CRBN	BCR-ABL T315I	Inquiry
Molecular Weight: 901.95 Molecular Formula: C48H46F3N9O6 Boiling Point: 1016.7±65.0°C at 760 Torr Density: 1.46±0.1 g/cm3 Description: It is a selective BCR-ABL T315I proteolysis-targeting chimeric (PROTAC) degrader based on GZD824.
	BPL-202623	3-((1H-Pyrazolo[3,4-b]pyridin-5-yl)ethynyl)-N-(4-((4-(9-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-9-oxononyl)piperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-4-methylbenzamide	2703834-26-6	CRBN	BCR-ABL T315I	Inquiry
Molecular Weight: 929.99 Molecular Formula: C50H50F3N9O6 Boiling Point: 1026.0±65.0°C at 760 Torr Density: 1.44±0.1 g/cm3 Description: It is a selective BCR-ABL T315I proteolysis-targeting chimeric (PROTAC) degrader based on GZD824.
	BPL-202624	3-((1H-Pyrazolo[3,4-b]pyridin-5-yl)ethynyl)-N-(4-((4-(11-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-11-oxoundecyl)piperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-4-methylbenzamide	2703834-27-7	CRBN	BCR-ABL T315I	Inquiry
Molecular Weight: 958.06 Molecular Formula: C52H54F3N9O6 Boiling Point: 1030.3±65.0°C at 760 Torr Density: 1.41±0.1 g/cm3 Description: It is a selective BCR-ABL T315I proteolysis-targeting chimeric (PROTAC) degrader based on GZD824.
	BPL-202625	3-((1H-Pyrazolo[3,4-b]pyridin-5-yl)ethynyl)-N-(4-((4-(13-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-13-oxotridecyl)piperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-4-methylbenzamide	2703834-28-8	CRBN	BCR-ABL T315I	Inquiry
Molecular Weight: 986.11 Molecular Formula: C54H58F3N9O6 Boiling Point: 1040.6±65.0°C at 760 Torr Density: 1.38±0.1 g/cm3 Description: It is a selective BCR-ABL T315I proteolysis-targeting chimeric (PROTAC) degrader based on GZD824.
	BPL-202626	3-((1H-Pyrazolo[3,4-b]pyridin-5-yl)ethynyl)-N-(4-((4-(15-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-15-oxopentadecyl)piperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-4-methylbenzamide	2703834-29-9	CRBN	BCR-ABL T315I	Inquiry
Molecular Weight: 1014.16 Molecular Formula: C56H62F3N9O6 Boiling Point: 1051.1±65.0°C at 760 Torr Density: 1.36±0.1 g/cm3 Description: It is a selective BCR-ABL T315I proteolysis-targeting chimeric (PROTAC) degrader based on GZD824.
	BPL-202627	(1S,3R,7S,8S,8aR)-8-(2-((2R,4R)-4-Hydroxy-6-oxotetrahydro-2H-pyran-2-yl)ethyl)-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl (3-(2-(2-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)propoxy)ethoxy)ethoxy)propyl)carbamate	2715104-40-6	CRBN	HMGCR	Inquiry
Molecular Weight: 822.95 Molecular Formula: C43H58N4O12 Boiling Point: 1002.3±65.0°C at 760 Torr Density: 1.32±0.1 g/cm3 Description: It is an orally active VHL-recruiting PROTAC that achieves robust HMGCR degradation and potent hypolipidemic activity in vivo.
	BPL-202628	(1S,3R,7S,8S,8aR)-8-(2-((2R,4R)-4-Hydroxy-6-oxotetrahydro-2H-pyran-2-yl)ethyl)-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl (2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethyl)carbamate	2715104-41-7	CRBN	HMGCR	Inquiry
Molecular Weight: 750.85 Molecular Formula: C39H50N4O11 Boiling Point: 978.5±65.0°C at 760 Torr Density: 1.36±0.1 g/cm3 Description: It is an orally active VHL-recruiting PROTAC that achieves robust HMGCR degradation and potent hypolipidemic activity in vivo.
	BPL-202629	(1S,3R,7S,8S,8aR)-8-(2-((2R,4R)-4-Hydroxy-6-oxotetrahydro-2H-pyran-2-yl)ethyl)-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl (3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)propyl)carbamate	2715104-42-8	CRBN	HMGCR	Inquiry
Molecular Weight: 676.77 Molecular Formula: C36H44N4O9 Boiling Point: 945.9±65.0°C at 760 Torr Density: 1.37±0.1 g/cm3 Description: It is an orally active VHL-recruiting PROTAC that achieves robust HMGCR degradation and potent hypolipidemic activity in vivo.
	BPL-202630	(1S,3R,7S,8S,8aR)-8-(2-((2R,4R)-4-Hydroxy-6-oxotetrahydro-2H-pyran-2-yl)ethyl)-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl (8-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-8-oxooctyl)carbamate	2715104-44-0	VHL	HMGCR	Inquiry
Molecular Weight: 918.21 Molecular Formula: C50H71N5O9S Boiling Point: 1106.0±65.0°C at 760 Torr Density: 1.25±0.1 g/cm3 Description: It is an orally active VHL-recruiting PROTAC that achieves robust HMGCR degradation and potent hypolipidemic activity in vivo.
	BPL-202631	(1S,3R,7S,8S,8aR)-8-(2-((2R,4R)-4-Hydroxy-6-oxotetrahydro-2H-pyran-2-yl)ethyl)-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl (11-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-11-oxoundecyl)carbamate	2715104-45-1	VHL	HMGCR	Inquiry
Molecular Weight: 960.29 Molecular Formula: C53H77N5O9S Boiling Point: 1113.1±65.0°C at 760 Torr Density: 1.23±0.1 g/cm3 Description: It is an orally active VHL-recruiting PROTAC that achieves robust HMGCR degradation and potent hypolipidemic activity in vivo.
	BPL-202632	(3R,5R)-3,5-Dihydroxy-7-((1S,2S,6R,8S,8aR)-8-(((11-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-11-oxoundecyl)carbamoyl)oxy)-2,6-dimethyl-1,2,6,7,8,8a-hexahydronaphthalen-1-yl)heptanoic acid	2715104-46-2	VHL	HMGCR	Inquiry
Molecular Weight: 978.31 Molecular Formula: C53H79N5O10S Boiling Point: 1141.4±65.0°C at 760 Torr Density: 1.24±0.1 g/cm3 Description: It is an orally active VHL-recruiting PROTAC that achieves robust HMGCR degradation and potent hypolipidemic activity in vivo.